Posts

 

NIH alone awards roughly $6B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle, from basic research, through pre-clinical activities and early phase clinical trials.

In this webinar, we discuss key cancer related opportunities, focusing on the new set of solicitations from the National Cancer Institute (NCI) and the soon to be released CDMRPs (DoD) that are available for life science organizations.

 

View Slide Deck

Dr. Charles Cywin of the National Institute of Neurological Disorders and Stroke spoke about the programs available to support neuroscience translational research.

View Slide Deck

Dr. Matthew Portnoy of the National Institutes of Health gave updates on the Small Business Innovation Research and Small Business Technology Transfer Programs.

View Slide Deck

Adam Ruben

doi:10.1126/science.caredit.a1600164

‘Twas the night before grant deadline, 7:15.
Many creatures were stirring, thanks to caffeine.
The comments accepted, the references done,
In hopes someone might fund my first R01.

I wrote like a showman. My prose was terrific.
My font was New Roman. My aims were specific.
I showed prior data and new innovation—
I even nailed my budget justification.

The footnotes were hung like superscript pendants,
Each at the end of a well-crafted sentence.
I sighed with relief; it had all turned out fine,
And I dreamed of the day when I’d hear the pay line.

I’d labored for months while my spouse gazed with pity:
This would have to influence my tenure committee.
The time and the effort I’d spent really showed.
Now the grant was complete; it was time to upload.

When what should my wondering eyes chance to scan
But the tiniest typo in my research plan?
Then more and more errors came as I read through!
And I knew it would never survive peer review.

So quickly I rose from my chair made of vinyl
And opened the files I’d all labeled “FINAL.”
“Sweet merciful Darwin!” I cried to the heavens.
“There’s no Figure 6! There are two Figure 7s!”

My spacing was shrunk and my margins too wide!
My titles and headings were right-justified!
Even the sections I’d thought in grand shape
Had been converted from portrait to landscape!

What fate had befallen my grant so idyllic?
The tables were merged—and is that Cyrillic?
So many errors! Oh, how could this be?
All I did was convert from Mac to …

Uh-oh.

Now swiftly I read one line to the next,
Putting symbols back in and repairing the text,
Fixing all of the words over which I had sweated,
The objects and worksheets that now were embedded.

“But it’s science!” I screamed, my heart pitter-patting.
“Why must I spend all my time on formatting?
Why would anyone panic? Why would they care if
My spacing was close, or my font had a serif?”

When all of a sudden, there came such a din
That I ran to the door—and then he walked in.
“Cease your worry!” said he, in his bold way of talking.
“All good scientists get a grant in their stocking.

You’ve done all the research that one could deem prudent.
(Well, not you—your postdocs and graduate student.)
Your grant is the greatest thing since streptomycin!”
And I knew right away he was Neil deGrasse Tyson.

He was dressed in a blazer; his elbows were patched.
And, like most astronomers, none of it matched.
His mustache, so bushy! His loafers, how dirty!
His visage, so kind, and his necktie, how nerdy!

“Oh please, Dr. Tyson!” I then interrupted.
“The grant is due soon, and my file’s corrupted!
If my department chair sees that I’ve flunked,
I might be demoted to teaching adjunct!”

With a wink and a nod and a friendly high-five,
He placed in my hand a USB drive.
The files it held were my own grant, but better!
He even provided a new cover letter!

As I marveled and gawked at my mended submission,
With every page break in its proper position,
He climbed in his sleigh. (Why a sleigh? Don’t ask me.)
He took up the reins, and he shouted with glee:

“Now funding! Now finance! Now tech transfer offers!
On private foundations! On government coffers!
Now sit back and watch as your budget increases
For keeping your postdocs on H1-B visas!”

“Oh, thank you!” I yelled, “for each PDF’d page!
My lab techs will cheer at their new living wage!
On supplies and equipment we’ll run up a tab.
My undergrads won’t have to sleep in the lab!”

I dreamed of results from the money we’d spend,
Professional meetings we now could attend,
The safety routines we’d bring up to compliance,
The last-author papers I’d publish in Science.

For grant applications are vaguely abusive;
Funding is fleeting and tenure elusive.
In science, we struggle for basic support.
I guess we’re less vital than, say, a sport.

He pointed his sleigh toward a twinkling star,
Then flew off to help with an SBIR.
And I heard him exclaim, in a voice to enchant,
“Merry deadline to all! Now go start your next grant.”

 

Read online

In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies.

The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation.

In this webinar, FreeMind experts discuss the latest trends at the NIH and the funding opportunities available with respect to medical devices.

View Slide Deck

Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding over 1000 projects in the excess of $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations and partnerships between domestic and foreign entities, the funded R&D dollars outside the US even exceed the above.

In this presentation, we provide insight into the non-dilutive funding landscape with an emphasis on the NIH, Department of Defense and other government agencies. FreeMind experts will describe the various pockets of money available for non-US applicants, potential for funding, and means to maximize chances for award.

View Slide Deck

Sep 07, 2017

NEW YORK (GenomeWeb) – The US Senate’s appropriations committee today approved a funding bill that would increase the National Institutes of Health’s fiscal 2018 budget by $2 billion to $36.1 billion.

The bill — which was cleared by the Senate Labor, Health and Human Services, and Education Appropriations Subcommittee yesterday — was approved by the full appropriations committee by a 30-1 vote.

Of the total allocated to the NIH, $1.8 billion is earmarked for Alzheimer’s disease research, representing a $414 million increase over fiscal 2017; $400 million for the BRAIN Initiative, $140 million more than last fiscal year; and a $60 million increase to $290 million for the All of Us precision medicine program. The National Cancer Institute’s precision medicine program received a $10 million increase to $80 million under the fiscal 2018 funding bill; while $513 million was committed to fighting antibiotic-resistance bacteria, a $50 million increase over the previous fiscal year.

“This bill upholds important investments in programs that affect all Americans,” Appropriations Committee Chairman Senator Thad Cochran (R-MS) said in a statement. “It deserves consideration by the Senate.”

Source: https://www.genomeweb.com/policy-legislation/senate-appropriations-committee-clears-2b-boost-nih-budget

Every year, US-based non-dilutive sources of funding award billions of dollars towards clinical stage research in the Life Sciences.

Funding is available for clinical stage funding across scientific fields including Infectious Diseases, Neurosciences, Cardiovascular, and many more. These funds come from multiple Institutes within the NIH, such as NIAID, NIAMS, NIDDK, from BARDA, and from the DOD.

In this webinar, we discuss the process for applying, guidelines, key success components and insight into increasing chances for award.

 

View Slide Deck